PAVBLU
Biological
Amgen Inc.
Total Payments
$133,625
Transactions
69
Doctors
29
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $133,625 | 69 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,877 | 25 | 67.3% |
| Unspecified | $39,717 | 4 | 29.7% |
| Travel and Lodging | $2,917 | 11 | 2.2% |
| Food and Beverage | $1,115 | 29 | 0.8% |
Payments by Type
General
$93,908
65 transactions
Research
$39,717
4 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ABP 938 Global P3 Study | Amgen Inc. | $39,717 | 0 |
Ad
Manufacturing Companies
- Amgen Inc. $133,625
Product Information
- Type Biological
- Total Payments $133,625
- Total Doctors 29
- Transactions 69
About PAVBLU
PAVBLU is a biological associated with $133,625 in payments to 29 healthcare providers, recorded across 69 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2024 to 2024. In 2024, $133,625 was paid across 69 transactions to 29 doctors.
The most common payment nature for PAVBLU is "Consulting Fee" ($89,877, 67.3% of total).
PAVBLU is associated with 1 research study, including "ABP 938 Global P3 Study" ($39,717).